Brokerages Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Target Price at $45.25

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) has received an average recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $45.25.

Several analysts recently commented on the company. Leerink Partners reiterated an “outperform” rating and set a $36.00 price target (down from $40.00) on shares of 4D Molecular Therapeutics in a research report on Thursday, September 19th. BMO Capital Markets dropped their price target on 4D Molecular Therapeutics from $63.00 to $40.00 and set an “outperform” rating for the company in a research report on Thursday, July 18th. Cantor Fitzgerald lowered 4D Molecular Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, September 23rd. Chardan Capital boosted their price objective on 4D Molecular Therapeutics from $38.00 to $39.00 and gave the stock a “buy” rating in a research note on Thursday, September 19th. Finally, HC Wainwright reissued a “buy” rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a research note on Thursday, September 19th.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Several large investors have recently modified their holdings of FDMT. nVerses Capital LLC acquired a new position in shares of 4D Molecular Therapeutics in the 3rd quarter valued at $40,000. Allspring Global Investments Holdings LLC lifted its stake in shares of 4D Molecular Therapeutics by 702.1% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 3,457 shares of the company’s stock valued at $110,000 after purchasing an additional 3,026 shares during the last quarter. Quest Partners LLC lifted its stake in shares of 4D Molecular Therapeutics by 17,409.1% in the 2nd quarter. Quest Partners LLC now owns 5,778 shares of the company’s stock valued at $121,000 after purchasing an additional 5,745 shares during the last quarter. Entropy Technologies LP acquired a new position in shares of 4D Molecular Therapeutics in the 1st quarter valued at $239,000. Finally, Hsbc Holdings PLC acquired a new position in shares of 4D Molecular Therapeutics in the 2nd quarter valued at $246,000. Institutional investors and hedge funds own 99.27% of the company’s stock.

4D Molecular Therapeutics Stock Performance

Shares of FDMT opened at $8.53 on Friday. 4D Molecular Therapeutics has a one year low of $8.37 and a one year high of $36.25. The stock has a market capitalization of $441.03 million, a price-to-earnings ratio of -3.50 and a beta of 2.77. The stock has a 50 day moving average price of $13.03 and a 200 day moving average price of $19.51.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.09. The firm had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $1.90 million. On average, analysts predict that 4D Molecular Therapeutics will post -2.74 earnings per share for the current year.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.